Viatris is bucking the trend of major pharma players exiting the consumer health market by partially reversing its decision to divest its OTC business.
The Canonsburg, PA-based firm described OTC as “non core” in November 2022 as it put the business up for sale along with its women’s healthcare and active pharmaceutical ingredients operations
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?